Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery

Xiaobei Pan1, Emma L. Cunningham1,2, Anthony P. Passmore2, Bernadette McGuinness2, Daniel F. McAuley1, David Beverland4, Seamus O’Brien4, Tim Mawhinney5, Jonathan M. Schott6, Henrik Zetterberg7,8,9,10 & Brian D. Green1,11

Delirium is a marker of brain vulnerability, associated with increasing age, pre-existing cognitive impairment and, recently, cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease. This nested case-control study used a targeted quantitative metabolomic methodology to profile the preoperative CSF of patients (n = 54) who developed delirium following arthroplasty (n = 28) and those who did not (n = 26). The aim was to identify novel preoperative markers of delirium, and to assess potential correlations with clinical data. Participants without a diagnosis of dementia (≥65 years) undergoing elective primary hip or knee arthroplasty were postoperatively assessed for delirium once-daily for three days. Groups were compared using multivariate, univariate and receiving operator characteristic (ROC) methods. Multivariate modelling using Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) of metabolomic data readily distinguished between delirium and control groups (R2 ≤ 0.56; Q2 ≤ 0.10). Three metabolites (spermidine, putrescine and glutamine) significantly differed between groups (P < 0.05; FDR < 0.07), and performed well as CSF biomarkers (ROC > 0.75). The biomarker performance of the two polyamines (spermidine/putrescine) was enhanced by ratio with CSF Aβ42 (ROC > 0.8), and spermidine significantly correlated with Aβ42 (pearson r = −0.32; P = 0.018). These findings suggest that spermidine and putrescine levels could be useful markers of postoperative delirium risk, particularly when combined with Aβ42, and this requires further investigation.

Delirium is an acute confusional state1 which is unpleasant for patients, their families and healthcare staff2. It is associated with significant negative outcomes including dementia, institutionalisation and death3. Postoperative delirium is common, developing after 17% of planned joint replacement surgeries4. Delirium is a marker of brain

1Institute for Global Food Security, School of Biological Sciences, Queen’s University Belfast, 8 Malone Road, Belfast, BT9 5BN, Northern Ireland. 2Centre for Public Health, Queen’s University Belfast, Block B, Institute of Clinical Sciences, Royal Victoria Hospital site, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland. 3Centre for Experimental Medicine, Queen’s University Belfast, Wellcome-Wolfson Institute for Experimental Medicine, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland. 4Outcomes Assessment Unit, Musgrave Park Hospital, Belfast Trust, Stockman’s Lane, Belfast, BT9 7JB, Northern Ireland. 5Cardiac Surgical Intensive Care Unit, Belfast Trust, Royal Victoria Hospital, Grosvenor Road, Belfast, BT12 6BA, Northern Ireland. 6Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, UK, Box 16, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK. 7UK Dementia Research Institute at UCL, Cruciform Building, Gower Street, London, WC1E 6BT, UK. 8Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK, Box 16, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK. 9Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, House V, S-431 80 Mölndal, Göteborg, Sweden. 10Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, BLÅ Stråket 15, S-413 45, Gothenburg, Sweden. 11Core Technology Unit for Mass Spectrometry, Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, UK. Xiaobei Pan and Emma L. Cunningham contributed equally. Correspondence and requests for materials should be addressed to E.L.C. (email: emma.cunningham@qub.ac.uk)
vulnerability, associated with increasing age, pre-existing cognitive impairment\(^5\,6\) and, recently, cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD)\(^7\).

Whilst the pathophysiological basis for delirium remains unclear, it is thought to represent, at least partly, an aberrant stress response\(^8\).

Metabolomics is a relatively new technique which can comprehensively and simultaneously detect disturbances in the metabolome in a high-throughput manner\(^9,10\). As metabolomics directly measures chemical processes involving metabolites, it holds huge potential as a discovery platform for identifying novel diagnostic biomarkers and elucidating disease pathogenesis. The metabolomic analysis of brain tissue, CSF and plasma has advanced our understanding of the processes leading ultimately to dementia\(^11\,12\).

Two previous studies have investigated the alteration of metabolites to samples from delirium and no delirium groups in a fracture population, one studying plasma samples\(^14\) and one utilising both blood and CSF\(^15\). Guo et al. reported multiple preoperative metabolic pathways disturbance in postoperative delirium groups including deficiency of \(\omega_3\) and \(\omega_6\) fatty acids, energy metabolism and oxidative stress with interactions between hypoxia and mitochondrial dysfunction, as well as disorders in the Glu–Gln cycle\(^14\). Watne et al. applied high performance liquid chromatography (HPLC) to measure amino acids and monoamine metabolites in CSF and serum and found increased levels of methionine, phenylalanine, tryptophan and tyrosine in fracture patients who went on to develop postoperative delirium\(^15\). Fracture patients are older and sicker at baseline\(^16,17\), have by definition already experienced trauma and often have preoperative delirium\(^18\). Elective orthopaedic populations, by contrast, permit comprehensive preoperative and premorbid cognitive assessment and CSF sampling at a clinically homogenous point, whilst still seeing a significant incidence of delirium.

The aim of the current nested case-control study was to employ a targeted quantitative metabolomic methodology to profile the CSF metabolome of patients who developed delirium following arthroplasty compared to those who did not. The aim was to test the hypothesis that CSF metabolomic profiles differ in those who developed delirium following arthroplasty from those who did not.

**Methods**

**Study population.** Participants aged 65 years or older admitted for primary elective hip or knee arthroplasty to a single surgical centre and planned to undergo spinal anaesthesia with intrathecal diamorphine analgesia were eligible for inclusion. Exclusion criteria included a pre-existing diagnosis of dementia or other neurodegenerative condition. Between March 2012 and October 2014, 315 participants completed the study. Average age was 74.4 years and 57% were female. American Society of Anesthesiologists (ASA) physical status classification was available for 53 of the 54 participants. Of these, one participant was ASA 1, 43 were ASA 2 and nine were ASA 3. The incidence of postoperative delirium in our cohort was 44/315 (14%).

**Study Methods.** Study methods are summarised in Fig. 1. Written informed consent was obtained from all participants and the study was approved by, and performed in accordance with, local ethical committee procedures (Office for Research Ethics Committees Northern Ireland; REC reference: 10/NIR01/5; protocol number: 09069PP-OPMS). Demographic data and potential confounding variables including age, gender, type of surgery, Charlson Comorbidity Index (CCI)\(^19\), level of education, estimated IQ\(^20\) and the Vertical Visual Analogue Pain Scores\(^21\) were collected preoperatively and included in analyses. Baseline neuropsychological tests included Colour Trails\(^22\) and Mini Mental State Examination\(^23\).

Postoperatively participants were assessed for delirium once daily by a single researcher for the first three days. Delirium was diagnosed using the Confusion Assessment Method (CAM)\(^24\) and daily assessments were supplemented by post-discharge reviews of the nursing and medical notes. In all cases where there were reports of possible delirium but CAM criteria were not fulfilled, cases were then discussed between ELC and APP and a consensus reached as to whether they reflected delirium according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria\(^25\).
DNA collection, processing and analysis. Venous blood was sampled preoperatively into PAXgene DNA tubes (PreAnalytiX; Qagen/BD, Catalogue No. 761125). All samples were transported to the laboratory within 12 hours of collection.

DNA samples were processed according to the manufacturer’s instructions (TaqMan Single Nucleotide Polymorphism Genotyping Assay; Life Technologies; Catalogue No. 4351379).

DNA was analysed using the TaqMan Single Nucleotide Polymorphism Genotyping Assay (Life Technologies; Catalogue No. 4351379) as per the manufacturer’s instructions. APOE status was inferred from the genotype at each of the two alleles, rs7412 and rs429358.38

CSF collection and processing. Spinal anaesthesia was carried out, fasting, in the sitting or lateral positions using 25 gauge (diameter 0.53 mm; length 90 mm) Whitacre type spinal needles with graduated metal introducers (Vygon). Once CSF was obtained, a 5 ml syringe (BD Plastipak; BD) was attached to the spinal needle and up to 5mL of CSF withdrawn by the anaesthetist. The CSF was immediately transferred to a 30 ml sterile polypropylene universal container (Unisurge) which was placed on wet ice in an insulated container.

All samples were transported to the laboratory within 12 hours of collection. CSF samples were centrifuged at 4 °C at 3000 rpm/1811 g for 5 minutes with no brake and 500 mcl aliquots of the supernatant pipetted (Sarstedt, Germany, Catalogue No. 70.762) into 1.5 ml polypropylene tubes (Sarstedt, Germany, Catalogue No. 72.69.001) and stored at −80°C.

CSF analysis for Aβ42, T-tau and P-tau. CSF samples were transported to the Leonard Wolfson Biomarker Laboratory, University College London on dry ice. There Aβ42, T-tau and P-tau were analysed by a single, trained, technician, blinded to the clinical data, using the INNOTEST 3-amyloid (1–42), hTau Ag and Phospho-tau (181 P) ELISA kits respectively (Fujirebio, Ghent, Belgium) run on a FLUOstar Omega BMG LABTECH instrument (chemiluminescent plate reader) according to the manufacturer’s protocols. Samples were thawed at 21 °C in an air-conditioned lab and vortexed prior to use. CSF biomarker values were determined using Omega software (version 5.10 R2) and a 4-parameter curve fit. Intra- and inter-assay CVs, respectively, were 2.0% and 3.9% for Aβ42, 3.3% and 8.1% for T-tau and 1.6% and 5.1% for P-tau. Longitudinal stability in the measurements is further monitored in the laboratory by participation in the Alzheimer’s Association Quality Control program.39

Targeted metabolomics. Quantitative mass spectrometry-based metabolomic profiling was performed using the Biocrates AbsoluteIDQ p180 (BIOCRATES, Life Science AG, Innsbruck, Austria). All sample preparatory steps were carried out according to the manufacturer’s instructions36,39 and analysed on a triple-quadrupole mass spectrometer (Xevo TQ-MS, Waters Corporation, Milford, USA). The data were recorded in a 96-well format and seven calibration standards were integrated in the kit. Metabolites (amino acids and biogenic amines) were derivatised using phenylisothiocyanate (PITC) in the presence of isotopically labelled internal standards, separated using a UPLC (I-Class, Waters Corporation, UK) system with a reverse phase column (Waters ACQUITY UPLC BEH C18 2.1 × 50 mm, 1.7 µm; UK) and quantified using a triple-quadrupole mass spectrometer (Xevo TQ-MS, Waters Corporation, UK) operating in the multiple reaction monitoring (MRM) mode. All the remaining metabolites (acylcarnitines, hexoses, glycerophospholipids, and sphingolipids) were quantified using the same mass spectrometer without column separation by the flow injection analysis (FIA) operating in MRM mode. Metabolite concentrations were calculated and expressed as micromolar (µM). The mean of the coefficient of variation (CV) for the 180 metabolites in repeated quality controls was 0.12, and 85% of the metabolites had a CV of <0.15.

Statistical analysis. Powering of original study. The observational cohort study was powered to detect a difference in the risk of postoperative delirium between the APOE ε4 positive and negative groups based on an estimated APOE ε4 carrier rate of 25.5% and a rate of delirium in the APOE ε4-positive and APOE ε4-negative groups of 28% and 11%, respectively, in an elective non-cardiac surgery population. It was estimated that 316 participants would be required to enable detection of significant difference, at the 5% significance level, with 90% power.

Selection of cases and controls. Participants, with and without postoperative delirium, with sufficient CSF available to facilitate metabolomic analysis were identified. Samples for this study were selected primarily based on CSF availability. Availability of CSF was not associated with delirium in this cohort. Delirium and control groups were matched for age and gender. Initially two groups of n = 27 each were identified but when additional medical notes became available and were reviewed one participant was reclassified as having had delirium using the methods outlined above, leaving n = 28 cases and n = 26 controls.

Included covariates. Preoperative clinical variables previously shown to be associated with delirium in our cohort (Cunningham et al. 2017, Cunningham et al. 2018) were included in the analyses. Data for perioperative intravenous opioid use was insufficient and this was therefore excluded.

Statistical Analysis of Metabolomic Data. Concentration data for 187 metabolites were appropriately reformatted and exported to Simca 15 (Umetrics, Umeå, Sweden) for multivariate analysis. Data were grouped into delirium and control prior to analysis by principal component analysis (PCA) identifying any potential outliers, followed by partial least squares-discriminant analysis (PLS-DA). The validity of the model was evaluated based on the residuals (R2X, R2Y) and the model predictive ability parameter (Q2) determined through the default leave-1/7th-out cross validation. The number of components for the PLS-DA model was optimized using y-tables.
permutation testing (n = 500) and an ANOVA based on the cross-validated predictive residuals (CV–ANOVA)32. For CV–ANOVA assessment of significance, a p-value less than 0.05 was considered as significant. Variable importance in projection (VIP) plots was created to identify the top metabolites responsible for discriminating between groups. The normality of data were tested using SPSS (version 24). Student's t-test for metabolites exhibiting a normal distribution or the Wilcoxon Mann–Whitney test for metabolites exhibiting non-normal distributions, and false discovery rates (FDR, q-value) were performed to determine if metabolites were statistically different between two groups (p < 0.05, q < 0.07) (Metaboanalyst Version 3.5; (Xia et al., 2015). The FDR adjustment of P-values for multiple comparisons within Metaboanalyst applies the Benjamini & Hochberg correction method33. In order to assess and compare the biomarker performance of metabolites and/or Aβ42 receiver operating characteristic (ROC) curves were constructed (GraphPad Prism, version 6.0). This initially examined individual concentration data and subsequently assessed metabolite/Aβ42 ratios as a method of enhancing overall biomarker performance.

Results

Matching of Groups. The baseline characteristics of the delirium and control groups, matched for age and gender, are shown in Table 1.

Multivariate analysis of metabolomics and clinical data. A PLS-DA model using metabolomics data only (Fig. 2A) was able to discriminate the delirium from the control subjects. With 2 components, the PLS-DA model was able to discriminate the two groups with R2X(cum) = 0.178, R2Y(cum) = 0.707, Q2 = 0.175. CV-ANOVA was used to validate the model (p = 0.016). When the same PLS-DA model was then applied to the pre-existing variables (as listed in Table 1), the PLS-DA model could only discriminate two groups with R2X(cum) = 0.266, R2Y(cum) = 0.473, Q2 = 0.123 (Fig. 2B). The p value for CV-ANOVA was 0.122 for the model, representing a statistically non-validated separation between the two groups. In addition, the predictive ability of the same PLS-DA model was significantly improved with the addition of the metabolomics data: R2X(cum) = 0.147, R2Y(cum) = 0.779, Q2 = 0.24 (Fig. 2C). The p value for CV-ANOVA was 0.79 × 10^-3. The PLS-DA loading plots showed the most influential variables that led to the separation between two groups. Combining metabolomic and clinical data improved the predictive ability (Q2 values from 0.175 and 0.123 for metabolome and pre-existing variables respectively to 0.24 for combination) for discrimination between two groups. The model was also validated using a permutation analysis (n = 500, Supplementary Fig. 1), in which the lower Q2 intercept indicated the robustness of the model and lower risk of over-fitting. The top 20 discriminatory metabolites/pre-existing variables between two groups identified by Variable importance in projection (VIP) are shown in Table 2. The top 5 discriminatory variables consisted of 4 metabolites (spermidine, C16:1-OH, glutamine and putrescine) as well as CSF Aβ42 concentrations, of which spermidine, C16:1-OH and glutamine contributed more for discrimination between two groups than Aβ42 concentration. The top 20 discriminatory metabolites only and top 10 pre-existing variables only are shown in Supplementary Tables 1 and 2.

Metabolites significantly altered in delirium group. Table 3 shows the CSF metabolites significantly altered in the delirium patients compared with control group using univariate analysis. P values from t-test, FDR q values, fold-change and ROC (AUC) were evaluated. Three metabolites (spermidine, glutamine and putrescine) were significantly different between the two groups with p values ≤ 0.05 and q values ≤ 0.07. As gender may significantly influence some metabolites34,35, spermidine, glutamine and putrescine are presented, in delirium and control subjects, grouped by gender in Fig. 3.

| Table 1. Baseline characteristics for delirium and control groups. |
|---------------------------------------------------------------|
| **Parameter** | **Delirium** | **Control** | **Statistical Test** | **P value** |
| Age, mean (SD) | 76.2 (5.7) | 75.9 (5.2) | t = 0.224 | 0.82 |
| Gender, female (%) | 15/28 | 14/26 | X2 = 0.0 | 1.00 |
| Type of Surgery (hip vs knee), hip (%) | 9 out of 28 | 15 out of 26 | X2 = 2.604 | 0.11 |
| Charlson Comorbidity Index 0/1/2/3 (md = 2) | 10/12/3/1 | 16/8/2/0 | MWU | 0.09 |
| Vertical Visual Analogue Pain Scale pain at rest, mean (SD) | 19.7 (24.9) | 26.5 (22.7) | t = -1.0 | 0.31 |
| Apolipoprotein, ApoE4 yes (%) (md = 1) | 9/27 | 8/26 | X2 = 0 | 1.00 |
| Years in Education, mean (SD) | 11.3 (1.8) | 11.4 (2.3) | t = -0.3 | 0.76 |
| Estimated IQ, mean (SD) | 106.8 (9.3) | 111.7 (7.5) | t = -2.1 | 0.04 |
| Mini Mental State Examination Score, mean (SD) | 26.0 (2.8) | 27.7 (1.9) | t = -2.5 | 0.02 |
| Time taken to complete Colour Trails 2 (seconds), mean (SD) | 205.2 (115.1) | 146.4 (50.2) | t = 0.2 | 0.12 |
| Qah, mean (SD) | 6.8 (3.2) | 5.9 (2.3) | t = 1.2 | 0.26 |
| CSF AB42, mean (SD) | 453.0 (175.8) | 613.9 (190.3) | t = -3.2 | <0.01 |
| CSF p-tau, mean (SD) | 63.9 (23.5) | 51.6 (22.0) | t = 2.0 | 0.05 |
| CSF t-tau, mean (SD) | 401.0 (233.0) | 291.3 (181.7) | t = 1.9 | 0.06 |
| p-tau/AB42 ratio | 0.17 (0.09) | 0.10 (0.08) | t = 2.9 | <0.01 |
Correlations between the significantly altered metabolites and A\(\beta\)\(_{42}\). We reported in our previous publication\(^7\) that patients who developed delirium had a 26\% lower CSF A\(\beta\)\(_{42}\) concentration in their pre-operative CSF. This was also highlighted in the VIP plots from the PLS-DA model (Table 2). Thus we evaluated the correlation between the A\(\beta\)\(_{42}\) and the significantly altered metabolites. Spermidine showed significantly negative correlation with A\(\beta\)\(_{42}\) with the Pearson \(r = -0.32\) and \(p = 0.018\) (Fig. 4). However, there was no significant correlation in glutamine and putrescine with A\(\beta\)\(_{42}\) (data not shown). The use of ratios of pairs of metabolites is a simple but powerful tool for enhancing biomarker performance\(^36\). Each metabolite was subjected to ratioing with A\(\beta\)\(_{42}\) and this led to improved AUROC values in the case of spermidine/A\(\beta\)\(_{42}\) and putrescine/A\(\beta\)\(_{42}\), but not glutamine/A\(\beta\)\(_{42}\) (Fig. 5).

Discussion
We have found that three amine/polyamine compounds – spermidine, glutamine and putrescine – are higher in preoperative CSF samples from persons who went on to develop delirium postoperatively than those who did not. The addition of metabolomic data to our statistical model increased the ability of the model to identify delirium susceptible patients within a population without dementia.

The elevation of polyamine pathway metabolites has previously been reported in brain tissue, plasma and CSF from AD patients\(^11,37,38\). Furthermore, there is evidence that polyamines are elevated in the brain and plasma animal models developing AD pathology\(^12\). Interestingly, it has been shown that polyamines can interact with and promote the aggregation of A\(\beta\) peptides\(^39\) forming amyloid plaques, which are a hallmark of AD. Moreover, the presence of A\(\beta\) peptides appears to increase polyamine metabolism by upregulating ornithine decarboxylase activity, which leads to increased polyamine synthesis\(^40,41\). These results therefore complement our previous findings that lower CSF A\(\beta\)\(_{42}\) (reflecting accumulation of aggregated A\(\beta\) in amyloid plaques in the brain\(^42\)) predicts postoperative delirium. Amyloid pathology causes impaired synaptic function and ultimately damages neurons,
resulting in cognitive impairment and finally dementia\(^3\); and likely therefore increases vulnerability to the effects of stressors, including opiates, pain, and inflammatory changes seen in surgery\(^4\), which may result in delirium. Understanding the biochemical basis for the development of postoperative delirium is a necessary first step if we are to intervene to reduce the incidence of this common, unpleasant and potentially dangerous syndrome. Identifying the pathways responsible may also enhance our understanding of neurodegeneration which predisposes to delirium. The study of elective orthopaedic populations permits comprehensive preoperative and premorbid cognitive assessment in contrast to research undertaken in fracture populations when participants are older and sicker at baseline\(^{16,17}\), have by definition already experienced trauma and often have preoperative

| Var ID (Primary) | M3.VIP[2] | 2.44693 * M3.VIP[2]cvSE |
|-----------------|-----------|-------------------------|
| 1 Spermidine    | 2.1055    | 1.50024                 |
| 2 C16:1-OH     | 2.02904   | 1.87932                 |
| 3 Glutamine     | 1.86714   | 1.22719                 |
| 4 Ab1-42 concentration | 1.76284 | 1.07464 |
| 5 Putrescine    | 1.74713   | 1.29829                 |
| 6 p-tau/AB42    | 1.65976   | 1.16424                 |
| 7 Serine        | 1.59627   | 1.19567                 |
| 8 Ornithine     | 1.55303   | 0.653106                |
| 9 Alanine       | 1.53883   | 0.798499                |
| 10 Threonine    | 1.52848   | 1.15706                 |
| 11 Valine       | 1.52002   | 1.14729                 |
| 12 Methionine   | 1.47764   | 0.979219                |
| 13 C4:2-OH      | 1.38247   | 1.95368                 |
| 14 MMSE         | 1.37368   | 1.69349                 |
| 15 Colour Trails 2 (seconds) | 1.35567 | 0.818909 |
| 16 C18:2        | 1.34463   | 1.34492                 |
| 17 Estimated IQ | 1.34086   | 1.94578                 |
| 18 p-tau concentration | 1.33876 | 1.04131 |
| 19 Lysine       | 1.28182   | 1.04599                 |
| 20 C4:1         | 1.2796    | 1.95744                 |

Table 2. Highest Ranking metabolites and pre-existing variables from Variable Importance Projection (VIP) based on the PLS-DA model.

| Metabolites | p value | FDR | ↑↓ | Fold change | ROC |
|-------------|---------|-----|----|-------------|-----|
| Spermidine  | 0.00014735 | 0.022545 | ↑ | 1.21 | 0.775 |
| Glutamine   | 0.00090092  | 0.045947  | ↑ | 1.12 | 0.794 |
| Putrescine  | 0.0017469   | 0.06682   | ↑ | 1.32 | 0.762 |

Table 3. List of metabolites significantly altered in the delirium group.

Figure 3. Box and whisker plots showing the three significantly altered metabolites grouped by gender.
delirium. The incidence of delirium is sufficiently high to study this condition, but low enough to likely indicate an underlying vulnerability. Although the findings of this nested case-control study are based on a relatively small sample and are not immediately translational, the key strengths include the use of fasting samples (all samples were preoperative), the detailed clinical information, and the annotated and quantitative metabolomic data.

Conclusions
This study indicates the benefits of applying metabolomic methodologies to conditions such as delirium to determine susceptibility risk: our findings suggest that CSF levels of spermidine, putrescine, and their metabolite precursor glutamine, could be useful markers of postoperative delirium risk, particularly when combined with Aβ42. The development of rapid and inexpensive methods of measuring spermidine and putrescine is needed to evaluate their utility in larger prospective patient cohorts, and to study whether CSF amines/polyamines are markers of underlying neurodegeneration (i.e. preclinical Alzheimer’s disease), or for delirium per se. Replication of these findings, in both delirium and AD cohorts, is now necessary.

Data Availability
The raw metabolomic data will be provided with this manuscript on request. After publication it will be submitted to an online data repository such as Metabolights. Readers can obtain further information on correspondence with the authors.

References
1. American Psychiatric Association. In Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Washington, DC, 2013).
2. Partridge, J. S., Martin, F. C., Harari, D. & Dhesi, J. K. The delirium experience: what is the effect on patients, relatives and staff and what can be done to modify this? Int. J. Geriatr. Psychiatry 28, 804–812 (2013).
3. Witlox, J. et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 304, 443–451 (2010).
4. Scott, J. E., Mathias, J. L. & Kneebone, A. C. Incidence of delirium following total joint replacement in older adults: a meta-analysis. Gen. Hosp. Psychiatry 37, 223–229 (2015).
5. Dasgupta, M. & Dumbrell, A. C. Preoperative risk assessment for delirium after noncardiac surgery: a systematic review. J. Am. Geriatr. Soc. 54, 1578–1589 (2006).
6. van Meenen, L. C., van Meenen, D. M., de Rooij, S. E. & ter Riet, G. Risk prediction models for postoperative delirium: a systematic review and meta-analysis. *J. Am. Geriatr. Soc.* 62, 2383–2390 (2014).
7. Cunningham, E. L. et al. CSF Beta-amyloid 1–42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study. *Ann. Surg.* (2018).
8. Macullich, A. M., Ferguson, K. J., Miller, T., de Rooij, S. E. & Cunningham, C. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. *J. Psychosom. Res.* 65, 229–238 (2008).
9. Beckonert, O. et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.* 2, 2692–2703 (2007).
10. Fiehn, O. Metabolomics—the link between genotypes and phenotypes. *Plant Mol. Biol.* 48, 155–171 (2002).
11. Graham, S. F. et al. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer’s disease. *PLoS One* 10, e0119452 (2015).
12. Pan, X. et al. Alzheimer’s disease-like pathology has transient effects on the brain and blood metabolome. *Neurobiol. Aging* 38, 151–163 (2016).
13. Gallart-Ayala, H. et al. A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: Exploring gender-associated variation in a cohort of elderly cognitively healthy subjects. *Analytica Chim. Acta* (2018).
14. Guo, Y. et al. Preoperative Serum Metabolites Are Associated With Postoperative Delirium in Elderly Hip-Fracture Patients. *J. Gerontol. A Biol. Sci. Med. Sci.* 72, 1689–1696 (2017).
15. Watne, L. O. et al. Increased CSF levels of aromatic amino acids in hip fracture patients with delirium suggests higher monoaminergic activity. *BMC Geriatr.* 16, 149-016-0324-0 (2016).
16. Royal College of Physicians. National Hip Fracture Database annual report 2017 (2017).
17. National Joint Registry. 14th Annual Report; National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. 14 (2017).
18. Bruce, A. J., Ritchie, C. W., Blizard, R., Lai, R. & Raven, P. The incidence of delirium associated with orthopedic surgery: a meta-analytic review. *International Psychogeriatrics* 19, 197–214 (2007).
19. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J. Chronic Dis.* 40, 373–383 (1987).
20. Nelson, H. E. & Willison, J. The National Adult Reading Test (NART) (1991).
21. Scott, J. & Huskisson, E. C. Vertical or horizontal visual analogue scales. *Ann. Rheum. Dis.* 38, 560 (1979).
22. D’Elia, L. F., Satz, P. J., Uchiyama, C. L. & White, T. Color trails test. Professional manual (1996).
23. Folstein, M. F., Folstein, S. E. & McHugh, P. R. “Mini-mental state” . A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198 (1975).
24. Inouye, S. K. et al. Clarifying confusion: the confusion assessment method. A new method for detecting of delirium. *Ann. Intern. Med.* 113, 941–948 (1990).
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Edition (2000).
26. Belbin, O. et al. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer’s disease. *Hum. Mol. Genet.* 16, 2199–2208 (2007).
27. Mattson, N. et al. CSF biomarker variability in the Alzheimer’s Association quality control program. *Alzheimers Dement.* 9, 251–261 (2013).
28. Nkiiou-Kenfack, E. et al. Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. *PLoS One* 9, e96955 (2014).
29. Romisch-Margl, W. et al. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. *Metabolomics* 8, 133–142 (2012).
30. McKay, G. J. et al. Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. *Ann. J. Epidemiol.* 173, 1357–1364 (2011).
31. Leung, J. M. et al. Apolipoprotein E ε4 allele increases the risk of early postoperative delirium in older patients undergoing noncardiac surgery. *Anesthesiology* 107, 406–411 (2007).
32. Eriksson, L., Trygg, J. & Wold, S. CV-ANOV A for significance testing of PLS and OPLS® models. *J. Chemometrics* 22, 594–600 (2008).
33. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (methodological)* 57, 289–300 (1995).
34. Audano, M., Maldini, D., De Fabiani, E., Mitro, N. & Caruso, D. Gender-related metabolomics and lipidomics: From experimental animal models to clinical evidence. *J. Proteomics* 88, 82–91 (2018).
35. Krumins, J. C. et al. Gender-specific pathway differences in the human serum metabolome. *Metabolomics* 11, 1815–1833 (2015).
36. Graham, S. F., Holscher, C. & Green, B. D. Metabolic signatures of human Alzheimer’s disease (AD): 1H NMR analysis of the polar metabolome of post-mortem brain tissue. *Metabolomics* 10, 744–753 (2014).
37. Inoue, K. et al. Metabolic profiling of Alzheimer’s disease brains. *Sci. Rep.* 3, 2364 (2013).
38. Trushina, E., Dutta, T., Persson, X. M., Mielke, M. M. & Petersen, R. C. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. *PLoS One* 8, e63644 (2013).
39. Luo, J. et al. Cellular polyamines promote amyloid-beta (Abeta) peptide fibrillation and modulate the aggregation pathways. *ACS Chem. Neurosci.* 4, 454–462 (2013).
40. Yatin, S. M., Yatin, M., Aulick, T., Ain, K. B. & Butterfield, D. A. Alzheimer’s amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. *Neurosci. Lett.* 263, 17–20 (1999).
41. Yatin, S. M., Yatin, M., Varadarajan, S., Ain, K. B. & Butterfield, D. A. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. *J. Neurosci. Res.* 63, 395–401 (2001).
42. Strozzyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. *Neurology* 60, 652–656 (2003).
43. Blennow, K., Mattsson, N., Scholl, M., Hansson, O. & Zetterberg, H. Amyloid biomarkers in Alzheimer’s disease. *Trends Pharmacol. Sci.* 36, 297–309 (2015).
44. Berger, M., Burke, J., Eckenhoff, R. & Mathew, J. Alzheimer’s disease, anesthesia, and surgery: a clinically focused review. *J. Cardiothorac. Vasc. Anesth.* 28, 1609–1623 (2014).

**Acknowledgements**

Many people contributed to the successful completion of this study. In particular we gratefully acknowledge the support of the anaesthetists, surgeons, theatre and ward staff of Musgrave Park Hospital; Mr John Conlon of the Centre for Experimental Medicine, QUB for technical laboratory support; Professor Chris Patterson of the Centre for Public Health for statistical support; Dr Rebecca Cairns and Ms Lauren Anderson for data inputting; Mrs Hazel Johnston and Mrs Elish Armstrong for neuropsychology training; the Leonard Wolfson Experimental Neurology Centre, especially Dr Amanda Heslegrave and Ms Elizabeth Halton and the Dementia Research Centre in UCL, especially Professor Nick Fox; the Cheung family for support via the Siew Keok Chin scholarship.
Alzheimer's Research UK (Metabolomic Analyses funded by Network Centre Pump Priming Grant). Cohort Study Funded by: Siew Keok Chin Scholarship (Philanthropic Funding). Belfast Arthroplasty Research Trust. Belfast Trust Charitable Funds.

Author Contributions
E.L.C. recruited participants, conducted neuropsychological assessments, processed samples, collated data, contributed to statistical analyses and drafted this manuscript along with X.P. X.P. undertook the metabolomic analyses, performed data analysis, and drafted the paper along with E.L.C. BMcG designed the cohort study, advised on analyses and edited the manuscript. A.P.P. designed the study, obtained the funding, has overall responsibility for the cohort study, contributed to delirium diagnoses, advised on analyses and edited the manuscript. D.F.McA. contributed to study design and management of the cohort study and edited the manuscript. D.F. was the surgeon responsible for all participants, contributed to study design and management and edited the manuscript. S.O.B. had responsibility for the set-up of the cohort study and edited the manuscript. T.M. recruited the first participants to the cohort study, conducted neuropsychological assessments, processed samples and approved the manuscript. J.M.S. recruited, designed the study, obtained the funding, has overall responsibility for the cohort study, contributed to CSF analyses and data interpretation in UCL and edited the manuscript. H.Z. oversaw CSF analyses in UCL and edited the manuscript. B.G. designed and oversaw metabolomic analyses, drafted, edited and takes responsibility for the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-40544-3.

Competing Interests: E.L.C., X.P., B.Mc.G., D.F.Mc.A., D.B., S.O.B, T.M. and B.G. declare no conflict of interest. P.P. has consulted for Pfizer, Eisai, Novartis, Janssen, Shire, Lundbeck, Nutricia. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. H.Z. has served at scientific advisory boards for Eli Lilly, Roche Diagnostics, Wave, Samumed and CogRx and has received travel support from Teva.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019